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Gain of 1q is one of the most common alterations in cancer and has been associated with adverse clinical behaviour in ependymoma.
The aim of this study was to investigate this region to gain insight into the role of 1q genes in intracranial paediatric ependymoma. To
address this issue we generated profiles of eleven ependymoma, including two relapse pairs and seven primary tumours, using
comparative genome hybridisation and serial analysis of gene expression. Analysis of 656 SAGE tags mapping to 1q identified CHI3L1
and S100A10 as the most upregulated genes in the relapse pair with de novo 1q gain upon recurrence. Moreover, three more
members of the S100 family had distinct gene expression profiles in ependymoma. Candidates (CHI3L1, S100A10, S100A4, S100A6
and S100A2) were validated using immunohistochemistry on a tissue microarray of 74 paediatric ependymoma. In necrotic cases,
CHI3L1 demonstrated a distinct staining pattern in tumour cells adjacent to the areas of necrosis. S100A6 significantly correlated with
supratentorial tumours (Po0.001) and S100A4 with patients under the age of 3 years at diagnosis (P¼0.038). In conclusion, this
study provides evidence that S100A6 and S100A4 are differentially expressed in clinically relevant subgroups, and also demonstrates
a link between CHI3L1 protein expression and necrosis in intracranial paediatric ependymoma.
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Identification of cancer-specific molecular alterations has had a
major impact on understanding the biology of cancer and impro-
ving treatment options in many cancers. For example, therapeutic
agents such as Imatinib (Gleevecs) targeting genes altered in the
cancer cell, but not in normal cells, are increasingly being tested in
the clinical setting. By systematically deciphering the genomes of
different cancers, frequent genomic aberrations and gene expres-
sion changes have been revealed and correlated with clinical
details. However, the biological and clinical relevance of most
aberrations in cancer is largely unknown. One such cancer, where
the investigation of the tumour-specific genetic aberrations would
have a major benefit upon the understanding of the disease that
could lead to better treatment choices and patient survival, is
ependymoma.
Ependymoma is the third most common brain tumour of
childhood, with around 50% occurring in infants younger than
5 years of age (Bouffet et al, 1998). Treatment and prognostication
is predominantly currently based on clinical criteria despite many
genomic studies identifying common molecular aberrations
(Reardon et al, 1999; Zheng et al, 2000; Scheil et al, 2001; Ward
et al, 2001; Carter et al, 2002; Dyer et al, 2002; Grill et al, 2002;
Jeuken et al, 2002; Gilhuis et al, 2004; Taylor et al, 2005; Suarez-
Merino et al, 2005; Mendrzyk et al, 2006; Modena et al, 2006;
Sowar et al, 2006; Lukashova-v Zangen et al, 2007). Currently
complete tumour resection is the only confirmed independent
prognostic marker, indicating a better patient outcome (Bouffet
et al, 1998; Sala et al, 1998). Despite complete resection, local
recurrence is reported in up to 50% of paediatric cases
(McLaughlin et al, 1998; van Veelen-Vincent et al, 2002). Some
improvements in survival rates have been seen over the last 30
years, with some 50% of patients now obtaining 5-year survival
(Gatta et al, 2003, 2005). However, when compared with other
cancers such as acute lymphoblastic leukaemia, where more than
80% of children are long-term survivors, these improvements lag
far behind. There is a need to identify robust biological markers
and to better understand the biology of ependymoma to improve
therapeutic strategies and patient survival.
Gain of 1q is one of the most common genomic aberrations in
cancer (Struski et al, 2002) and is frequently gained in ependy-
moma, occurring at an incidence of 420% (Reardon et al, 1999;
Scheil et al, 2001; Ward et al, 2001; Dyer et al, 2002; Grill et al,
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s2002). The gain of the whole of the q-arm of chromosome 1 has
been associated with a poor prognosis in ependymoma (Dyer et al,
2002), and has also been shown to adversely affect patient survival
in other paediatric cancers, including Wilms’ tumour and Ewing’s
sarcoma (Hirai et al, 1999; Hing et al, 2001). The region-specific
amplicon, 1q25, has been demonstrated as an independent
prognostic marker, indicating a poor prognosis (Mendrzyk et al,
2006). However, the mechanisms by which 1q, or 1q25, confer
adverse biological behaviour in ependymoma is unclear and a
more detailed analysis of 1q is necessary.
Chromosome 1q gain has also been shown to be the most
common global genetic change in ependymoma recurrent
tumours, seen in 67% of cases, with de novo gain of 1q frequently
occurring in the relapse sample (Dyer et al, 2002). The region-
specific amplicon 1q21.1–q32.1 has been associated with tumour
recurrence in intracranial ependymoma (Mendrzyk et al, 2006).
Several other region-specific amplicons frequently gained in
ependymoma include 1q21.3–q23.1, 1q21–q31 and 1q22–q31,
1q31.1–q31.3, 1q31–q32 and 1q41–qter (Kramer et al, 1998;
Scheil et al, 2001; Ward et al, 2001; Mendrzyk et al, 2006; Modena
et al, 2006). The 1q32 amplicon contains two genes laminin and
GAC1 that are overexpressed in ependymoma and the candidate
gene DUSP12 is located within the frequently gained ‘hotspot’
1q23.3 (Suarez-Merino et al, 2005; Mendrzyk et al, 2006). Despite
these observations the role of these amplicons remain unclear and,
to date, no specific genes on 1q have been shown to directly relate
to ependymoma tumorigenesis, relapse or patient outcome.
Taken together this evidence implicates the gain of 1q as a
marker for adverse clinical behaviour. However, the underlying
biology and the gene(s) involved remain to be elucidated.
To address these issues we used a combination of comparative
genome hybridisation (CGH) and serial analysis of gene expres-
sion (SAGE) to identify candidate genes on 1q. Candidates were
validated using immunohistochemistry (IHC) on a tissue micro-
array and the protein expression levels correlated with clinico-
pathological data to determine their potential role in intracranial
paediatric ependymoma.
MATERIALS AND METHODS
Sample cohort
For SAGE and CGH analysis, 11 fresh-frozen tumour samples
were obtained from the Duke Brain Tumour Bank, USA and
Birmingham Children’s Hospital, UK (Table 1). Five normal
brain libraries (white matter, cerebral cortex, paediatric frontal
cortex and two cerebellum) and six other brain tumour types
(one astocytoma grade I, eight astrocytoma grade II, 11 astro-
cytoma grade III, 10 glioblastoma, two oligodendroglioma and
20 medulloblastoma) were downloaded from the SAGE Genie
website (http://cgap.nci.nih.gov/SAGE; Boon et al, 2002).
For immunohistochemistry, a tissue microarray (TMA) was
constructed using formalin-fixed paraffin-embedded (FFPE)
tumour material from 74 primary tumours. The samples were
obtained from the Histopathology Department at the Birmingham
Children’s Hospital and further Neuropathology Departments of
the Children’s Cancer Leukaemia Group (CCLG) Centres. The
histology of each tumour was verified, representative areas were
identified by a pathologist (MAB) and a minimum of three cores
were taken. Haematoxylin and Eosin smears of corresponding
frozen material were used to confirm viable tumour. Clinical
information was obtained from the CCLG Data Centre, West
Midlands Children’s Tumour Registry and case notes.
CGH and SAGE libraries
Comparative genome hybridisation was performed as described by
Dyer et al (2002). Serial analysis of gene expression libraries were
constructed using the RNA isolated from 11 frozen tissue samples
as described by Boon and Riggins (2003). SAGE2000 software
(http://www.sagenet.org) was used to extract tags from the original
sequence files and processed to remove duplicate ditags, linker
sequences and repetitive tags. Tag counts and library information
for nine SAGE libraries have been posted to CGAP’s SAGE
Genie website (http://cgap.nci.nih.gov/SAGE) (Boon et al, 2002).
The complete list of genes mapping to chromosome 1q were
downloaded from the Ensembl genome browser (NCBI36) and the
best tag for each identified by searching the SAGE Genie website
(http://cgap.nci.nih.gov/SAGE) using the HUGO gene symbol. All
SAGE libraries were normalised to tags per 200000 to enable
cross-library comparison.
SAGE analysis
The SAGE data was analysed in four ways: (1) Tags were identified
in relapse pair R1 with a higher tag count in the relapsed sample
(E1023) than in the corresponding primary (E628). This data was
filtered to determine tags with either the same, or less, count in the
Table 1 Summary of clinical data, SAGE libraries and CGH profiles of 11 ependymoma
SAGE CGH
Library Age Sex P/R Location Total tags Unique tags Gains Losses Group
Relapse pair R1
1 E628 3 F P PF 120431 39836 None None B
2 E1023 7 F R PF 122690 40027 1q, 17q21-qtel 21q21-qtel S
Relapse pair R2
3 ER1p 2.5 M P PF 52490 21369 None None B
4 ER1r 4.7 M R PF 52910 20997 None None B
Primary only
5 E510 1.7 F P PF 84073 30595 None None B
6 E512 7 F P PF 75379 27374 9, 13, 14, 17q 1 S
7 E455 17 M P SP 51825 19611 NS NS —
8 E353 27 F P U 73822 27211 None None B
9 E580 29 M P PF 68614 25883 NS NS —
10 E582 31 M P SP 52189 17282 None None B
11 E239 34 F P PF 46653 20459 None 6,18, 22 S
B¼balanced; F¼female; NS¼not scoreable; M¼male; P¼primary; R¼recurrence; PF¼posterior fossa; S¼structural; SP¼spinal; U¼unknown. SAGE libraries 3 to 11 are
available to download from (http://cgap.nci.nih.gov/SAGE). Age is the age of the patient at diagnosis given in years.
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srelapse compared with the primary of R2. Tags were then ranked
based on the difference between the relapse and the primary of
pair R1. (2) The mean normalised tag counts were calculated for
the 656 1q tags across 10 ependymoma SAGE libraries and five
normal brain libraries to identify ependymoma-specific genes
(E1023 was removed from this analysis). Results were then sorted
based on the difference between the mean ependymoma and mean
normal brain tag count. (3) The data from (2) was filtered to
identify tags with p0.5 in normal brain and 42 in ependymoma,
then sorted by the highest ependymoma tag count. (4) The
mean tag count for each S100 gene was calculated across the six
different tumour types and fold changes between ependymoma
and normal brain and ependymoma and other brain tumour types
determined.
Immunohistochemistry
Immunohistochemical study was performed using a tissue
microarray of 74 FFPE tumours. Antibodies against the following
antigens were used: S100A10 (monoclonal, 1:8000; Swant,
Switzerland), S100A6 (monoclonal, 1:1000; Sigma-Aldrich),
S100A4 (polyclonal, 1:4000; Dako, UK); S100A2 (monoclonal,
1:500; Sigma-Aldrich) and CHI3L1 (1:1000; YKL-40; Quidel
Corporation, San Diego, CA, USA). Briefly, 5mm sections were
cut and incubated at 371C for 16h, de-paraffinised in xylene and
hydrated through decreasing concentrations of ethanol. Antigen
retrieval was performed in a pressure cooker in sodium citrate
buffer (pH 6.0) for 1min at full pressure. The TMAs were
incubated with normal goat serum followed by an endogenous
peroxidase block (Dako, Cambs, UK). The S100 antibodies were
incubated overnight at 41C. The Dako Chemate Envision Kit
(Dako, Cambs, UK) was used to detect the target antigen according
to the manufacturer’s instructions. Sections were then counter-
stained with haematoxylin (Surgipath, Cambs, UK), dehydrated
and mounted. The positive controls used were: for CHI3L,
glioblastoma; S100A2, skin and kidney; for S100A4, appendix
and liver; for S100A6 and S100A10 kidney. The slides were
examined by light microscopy with  10 and  40 objectives
(Olympus BX-41, UK) by two independent investigators including
a pathologist (MAB). Sections were then scored as described in
Figure 2.
Statistical analysis
Statistical analyses were performed using SPSS v15.0. Univariate
analysis of the association of protein expression levels with clinical
variables (Table 4) was assessed by Fisher’s exact test.
Kaplan–Meier survival curves were constructed to investigate
candidates as prognostic markers. Multivariate cox regression
hazard analysis was used to identify independent prognostic
markers. A P-value of o0.05 was considered statistically
significant and all values are given in Table 4.
RESULTS
Patients and CGH profiles
Genomic profiles were generated for 11 flash-frozen ependymoma
(Table 1). Of the nine tumours with a CGH profile, six tumours
(four paediatric and two adults) had a balanced genome (i.e., had
no detectable genomic losses or gains) and three (two paediatric
and one adult) had a structural genome (i.e., had few, mainly
partial chromosome gains). Two paediatric relapse pairs, R1 and
R2, were included in this study. Comparative genome hybridisa-
tion revealed that the recurrent sample (E1023) of relapse pair R1
had gain of 1q whereas the primary (E628) was balanced (i.e.,
de novo 1q gain). The genomes of the primary (E1p) and recurrent
sample (E1r) of relapse pair R2 were both balanced.
SAGE libraries and 1q tags
A total of 801076 SAGE tags were generated from 11 ependymoma
samples with, on average, over 26000 unique tags per library. The
complete libraries for 9 of the 11 ependymoma are available to
download from the SAGE Genie website. The unique SAGE tags
representing the genes on 1q were identified using the Ensembl
genome browser, reducing the number of tags to be analysed
to 656.
Upregulated genes associated with 1q gain in recurrent
ependymoma
From the filtered dataset of 656 1q tags, 205 were selected that had
a higher tag count in the relapse of pair R1 than in the
corresponding primary. To identify the genes upregulated on
account of gain of 1q, filtering was done to select tags that were
specifically upregulated upon relapse in the R1 pair compared with
the relapse pair R2. This reduced the number of tags to 149. Once
the tags were ranked based on the difference in tag count between
the recurrent sample of pair R1 and the primary, CHI3L1, S100A10
and PSMB4 were revealed as the top three genes upregulated as a
consequence of the gain of 1q in recurrent ependymoma (Table 2).
Ependymoma-associated 1q transcripts
A comparison of 1q tags in 10 ependymoma with five normal brain
libraries revealed S100A10 as the most upregulated gene (125.5
tags; Table 3). A second member of the S100 family, S100A6, was
identified with one of the highest differences between ependy-
moma and normal brain of 27.1. CHI3L1 also ranked highly, with a
Table 2 Most highly expressed genes in relapse pair with de novo 1q gain
SAGE TAG Gene ID Locus Gene title R1p R1r R2p R2r Difference
a
GTATGGGCCC CHI3L1 1q32.1 Chitinase 3-like 1 (cartilage glycoprotein-39) 38 326 30 0 288
AGCAGATCAG S100A10 1q21.3 S100 calcium-binding protein A10 122 322 76 11 200
ATCAGTGGCT PSMB4 1q21.3 Proteasome (prosome, macropain) subunit, b type, 4 41 84 41 18 43
TACTTTTGGC SLC41A1 1q32.1 Solute carrier family 41, member 1 11 34 15 7 23
TCAGTTTGTC HAX1 1q22 HS1-binding protein 11 34 26 18 23
GAGTGCAGGT TROVE2 1q31.2 TROVE domain family member 2 31 53 19 18 22
TACAGCACGG MGST3 1q24.1 Microsomal glutathione S-transferase 3 36 57 7 7 21
GTGTTTACGT RAB4A 1q42.13 RAB4A, member RAS oncogene family 8 26 15 0 18
TGCAATAAGC FAM36A 1q44 Protein FAM36A 6 24 22 15 18
TCTTTCCCCA PHLDA3 1q32.1 Pleckstrin homology -like domain, family A, member 3 0 16 7 3 16
Columns R1p, R1r, R2p and R2r show the tags per 200000 for the primary sample of relapse pair R1, relapse samples of relapse pair R1, primary sample of relapse pair R2 and
the relapse samples of relapse pair R2, respectively.
aThe difference was calculated using the formula (R1r-R1p).
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sdifference of 25.7 tags. When the data was then filtered for tags
meeting the criteria p0.5 mean tag count in normal brain but 42
tags in ependymoma, the uncharacterised gene C1orf192 showed
the highest difference in expression of 17.3 (Table 3). S100A4,
a third member of the S100 family, was also one of the most
upregulated genes in ependymoma with a difference in tag count
of 6.6.
S100 gene expression in ependymoma and other brain
tumours
Our analyses revealed that several members of the same gene
family were associated with 1q gain and were also upregulated in
ependymoma compared with normal brain tissue. Therefore, to
investigate this gene family, the mean tag counts were calculated
for all 14 S100 genes located on 1q21.3 represented in SAGE genie
in the ependymoma SAGE libraries (Figure 1). Of the 13 S100
genes, S100A4 had the highest mean tag count for ependymoma
relative to normal brain with a fold change of 20.7 and S100A10
had the highest mean tag count of 133 in ependymoma. S100A2
was the only S100 gene that was expressed in ependymoma but not
in normal brain with mean tag counts of 1.5 and zero, respectively.
No expression of five members of the S100 family (A15, A7, A5,
A14 and A13) was observed in ependymoma.
Members of the S100 family have been associated with different
cancers, including brain tumours. Therefore, this analysis was
extended to six other brain tumour types and the mean SAGE tags
were calculated for the 14 S100 genes in each tumour type
(Figure 1). S100A10 and S100A6 showed the highest mean
expression across the six brain tumour types of 43.6 and 41.7
tags, respectively. In both grade I astrocytoma and glioblastoma
(GBM) S100A10 had the highest tag count of 134 and 112.3,
respectively. S100A6 had the highest tag counts in oligodendro-
glioma (15 tags), medulloblastoma (10.4 tags) and grade II and III
Table 3 Most highly expressed genes associated with ependymoma
SAGE TAG Gene ID Locus Gene title Mean tumour
a Mean normal
b Difference
c
(b) Upregulated in ependymoma
AGCAGATCAG S100A10 1q21.3 S100 calcium-binding protein A10 132.9 7.4 125.5
GTCTGGGGCT TAGLN2 1q23.2 Transgelin 2 126.4 20 106.4
GGCTAATTAT ATP1A2 1q23.2 ATPase, Na+/K+ transporting, a 2 (+) polypeptide 146.3 70 76.3
TTTTTAATGT H3F3A 1q42.12 H3 histone, family 3A 96.6 24.6 72
GGCTGTACCC CSRP1 1q32.1 Cysteine and glycine-rich protein 1 146.4 79.2 67.2
TGAAGAGAAG PRDX6 1q25.1 Peroxiredoxin 6 47.2 6 41.2
CCCCCTGGAT S100A6 1q21.3 S100 calcium-binding protein A6 (calcyclin) 38.3 11.2 27.1
GTATGGGCCC CHI3L1 1q32.1 Chitinase 3-like 1 (cartilage glycoprotein-39) 26.5 0.8 25.7
TACATTCTGT MCL1 1q21.2 Myeloid cell leukaemia sequence 1 (BCL2-related) 27.4 5 22.4
TAATTCTTCT CCT3 1q23.1 Chaperonin containing TCP1, subunit 3 (g) 40.4 20.8 19.6
(c) Upregulated in ependymoma with p0.5 mean tag count in normal brain
ATCCAGACAG C1orf192 1q23.3 Chromosome 1 open reading frame 192 17.3 0 17.3
CCCAGATGAT SLC39A1 1q21.3 Solute carrier family 39 (zinc transporter), member 1 8.5 0.4 8.1
ATTCCTTTTT FMO3 1q24.3 Flavin containing monooxygenase 3 7.2 0 7.2
TAAGTCTATA FCGR2A 1q23.3 Fc fragment of IgG, low affinity IIa, receptor for (CD32) 6.6 0 6.6
TTCAAGATAC ANGPTL1 1q25.2 Angiopoietin-like 1 6.6 0 6.6
ATGTGTAACG S100A4 1q21.3 S100 calcium-binding protein A4 5.9 0.4 5.5
AGTGGTGGCT FMOD 1q32.1 Fibromodulin 5.7 0.4 5.3
ATCACACAGC LMOD1 1q32.1 Leiomodin 1 (smooth muscle) 4.4 0 4.4
TAGAAGGTGG C1orf54 1q21.2 Chromosome 1 open reading frame 54 4.8 0.4 4.4
GAAGCCAATG DISP1 1q41 Dispatched homologue 1 (Drosophila) 3.5 0.4 3.1
All tag counts are normalised per 200000 tags.
aMean tag count per individual tumour SAGE library.
bMean tag count per normal brain SAGE library.
cDifference between mean
tag count per ependymoma library and normal brain libraries.
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Figure 1 Summary of the mean SAGE tag counts for 14 S100 genes in ependymoma and six other brain tumour types (astrocytoma grade I, II, III,
glioblastoma, oligodendroglioma and medulloblastoma). The S100 genes are in genomic order and the start and end positions on chromosome 1 are given
in megabases (Mb).
aMean of the 52 SAGE libraries from the six brain tumour types. A red star marks the genes selected for further investigation.
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sastrocytoma (49.1 and 55 tags, respectively). Overall, S100A10 had
the highest fold change between ependymoma and other brain
tumours of three and S100A4 had the highest fold change between
ependymoma and normal brain of 20.7.
Differential expression of S100 proteins in intracranial
paediatric ependymoma
Four members of the S100 family were selected for further
investigation based on their distinct gene expression profiles in
ependymoma. Protein expression levels of S100A10, S100A6,
S100A4 and S100A2 were determined by immunohistochemistry
using an independent cohort of seventy-four primary paediatric
ependymoma arrayed on a tissue microarray (Figure 2A–H). One
of the eleven ependymoma samples used to create SAGE libraries,
ER1p, was represented on the TMA. In this sample, no gene or
protein expression was observed for S100A2 and S100A4 with
SAGE tag counts of 0 per 200000 tags and negative protein staining
observed by IHC. For S100A6 the SAGE tag count was 15 per
200000 tags and immunostaining determined as negative/weak.
Both gene and protein expression was observed for S100A10,
where the SAGE tag count was 76 per 200000 tags and moderate
protein expression was observed by IHC.
Univariate analysis was performed to explore possible asso-
ciations between the S100 protein expression levels and clinical
variables in primary ependymoma (Table 4). S100A6 significantly
correlated with tumours arising in the supratentorial region of the
brain (Po0.001) and S100A4 correlated with age at diagnosis
under 3 years (P¼0.038). No significant correlations were found
for S100A10 or S100A2. Kaplan–Meier survival analysis of the
clinical parameters and S100 protein expression showed that
resection status and tumour location were the only indicators of
prognosis, with complete resection and supratentorial tumours
indicating a better patient outcome (Po0.001 and P¼0.020,
respectively). Similarly, multivariate analysis revealed extent of
resection and tumour location as independent prognostic markers
(P¼0.007 and P¼0.001, respectively).
CHI3L1 expression in ependymoma
Forty-eight primary tumours were scored for CHI3L1 protein
expression. Tumours were categorised as having negative (0%),
weak (o25%) or strong (X25%) expression levels. Twenty-eight
(58%) were negative for CHI3L1 protein expression, 14 (29%)
showed weak and six (13%) demonstrated strong expression.
CHI3L1 protein expression was determined as weak for sample
ER1p, which had a SAGE tag count of 30 per 200000 tags. No
significant correlations with the clinical parameters investigated
were found. Histopathological review revealed that in five cases,
where areas of necrosis were visible, CHI3L1 protein expression
was restricted to the cytoplasm of viable tumour cells adjacent to
the areas of necrosis (Figure 2I and J).
DISCUSSION
Little is known about the genes and genetic mechanisms under-
lying ependymoma tumorigenesis, patient relapse and survival. To
address these issues we focused our study on chromosome 1q, one
of the most commonly gained regions in ependymoma. Using CGH
and SAGE profiling we identified CHI3L1 and members of the S100
family as candidate genes in ependymoma. Immunohistochemical
analysis on a large cohort of paediatric ependymoma revealed that
CHI3L1 protein expression is associated with necrosis and that
members of the S100 family are differentially expressed in
clinically relevant subgroups. S100A6 is significantly associated
with paediatric ependymoma arising in the supratentorial
compartment and S100A4 strongly correlates with patients aged
less than 3 years at diagnosis.
In this study, different approaches were taken to mine the
SAGE data to identify the ependymoma-associated genes on
AB
CD
EF
GH
IJ
Figure 2 Examples of immunohistochemical staining patterns of
S100A2, S100A4, S100A6, S100A10 and CHI3L1 on the paediatric
ependymoma tissue microarray. The tumour-specific staining pattern for
S100A2 (nuclear and/or cytoplasmic) was scored as either negative (0%;
A) or positive (40%; B). For S100A4 (nuclear and cytoplasmic staining)
cores were grouped as either negative/weak (o1%; C) or moderate
(X1%; D). S100A6 and S100A10 protein expression (cytoplasmic and/or
nuclear staining for A6 and membranous staining for A10, respectively) was
determined based on the percentage of immunopositive cells (0%; o10%;
X10% and 0%; o50%; X50%, respectively) ranging in intensity from
negative to strong (0 to 2þ). The cumulative scores denoted the
expression levels, which were grouped as either negative/weak or
moderate/strong for S100A6 (E, F) and S100A10 (G, H). CHI3L1
expression (cytoplasmic, granular) was scored as either negative (0%), weak
(o25%; I) or strong (X25%; J). Magnification  100 for all figures except
h, which is  10.
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schromosome 1q. Analysis of the effect of de novo 1q gain on gene
expression in recurrent ependymoma revealed that CHI3L1 was
the most highly expressed gene. Strikingly, four members of the
same gene family (S100A10, S100A6, S100A4 and S100A2) were
also identified as having distinct gene expression profiles in
ependymoma. Comparison of 10 ependymoma SAGE libraries with
five normal brain libraries identified S100A10 as the most highly
expressed gene on 1q in ependymoma; it was also the second most
highly expressed gene in the relapse sample with gain of 1q.
S100A6 was also identified as one of the most highly expressed
genes in ependymoma when compared with ‘normal’ brain.
S100A4, was implicated in ependymoma as, again, being one
of the most highly expressed genes in ependymoma with very
low expression in ‘normal’ brain. Analysis of all 1q S100 genes
represented in SAGE Genie identified S100A2 as the only S100 gene
expressed in ependymoma but not expressed at any level in
‘normal’ brain.
S100A10, S100A6, S100A4 and S100A2 are all members of the
S100 family of calcium-binding proteins and are located in a
cluster on 1q21.3; a region that has been shown to have both high
level gains (1q21–q31; Ward et al, 2001) and an association with
tumour recurrence in ependymoma (1q21.1–q23.1; Mendrzyk
et al, 2006). Members of the S100 family show divergent expression
patterns in a range of tissues and several have been linked with
cancer, including medulloblastoma (Hernan et al, 2003; Lindsey
et al, 2007) and astrocytoma (Camby et al, 1999, 2000). S100A6 has
been shown to clearly distinguish between low (WHO grade I
and II) and high (WHO grade III and IV) grade astrocytic tumours
(Camby et al, 1999). In ependymoma, we have clearly demon-
strated that S100A6 is differentially expressed in tumours arising
in different locations of the brain, and is significantly associated
with supratentorial tumours (Po0.001).
Clinically supratentorial ependymoma are associated with
better survival rates when compared with posterior fossa tumours
(Schiffer and Giordana, 1998). This survival difference could
be because of a number of confounding factors, for example,
the resectability of supratentorial when compared with infra-
tentorial tumours (Palma et al, 2000). There is now evidence
that ependymoma arising within different regions of the
central nervous system exhibit specific and distinct genetic
signatures (Taylor et al, 2005). For example, genes upregu-
lated specifically in supratentorial tumours include members
of the EPHB-EPHRIN and NOTCH cell-signalling systems.
Our observation of the differential expression of S100A6 in
different regions of the brain adds to this supratentorial gene
signature.
In ependymoma we have shown that S100A4 is significantly
associated with patients under the age of 3 years at diagnosis in
intracranial paediatric ependymoma (P¼0.038). Differences in the
genomic profiles between tumours from patients under the age
of 3 years and older children have previously been identified. For
example, balanced genomes (with no detectable genomic losses
and gains) are significantly associated with children younger than
3 years of age at surgery (Dyer et al, 2002). This finding suggests
that ependymoma occurring in patients less than 3 years are
biologically distinct from those occurring in older children. It has
been hypothesised that tumours occurring in infants may be
driven by powerful genetic events that lead to presentation at a
young age without the requirement for additional genetic changes
(Dyer et al, 2002). Although S100A4 is one of the best characterised
of the S100 genes in terms of its role in cancer (Emberley et al,
2004; Salama et al, 2007), no other study has previously reported a
link with patient age or explored its role in ependymoma. The
significance of S100A4 in ependymomas arising in children under
Table 4 Patient demographics, univariate and multivariate analysis of clinical and biological factors of 74 primary paediatric intracranial ependymoma
S100 protein
Gender Tumour location WHO grade Ageo3 years at diagnosis
a Resection status
4Patient demographics Sc % M F ST PF II III o3 43C I C
No. — — 41 33 19 55 49 35 34 40 26 44
% — — 55.4 44.6 25.7 74.3 66.2 33.8 45.9 54.1 37.1 62.9
4Univariate analysis P-value P-value P-value P-value
S100A2 1.000 1.000 1.000 0.551 —
Positive 14 21
Negative 51 79
Total scored 65 —
S100A4 0.598 0.252 0.788 0.038 —
Negative/weak 41 64
Moderate 23 36
Total scored 64 —
S100A6 0.549 0.000 1.000 0.236 —
Negative/weak 55 81
Moderate/strong 13 19
Total scored 68 —
S100A10 0.589 0.12 0.783 0.788 —
Negative/weak 21 35
Moderate/strong 39 65
Total scored 60 —
4Multivariate analysis
Hazard ratio — — 0.905 0.219 1.01 1.124 5.357
95% CI — — 0.451–1.816 0.072–0.662 0.448–2.278 0.561–2.251 2.080–13.792
P-value — — 0.778 0.007 0.981 0.742 0.001
C¼complete resection; CI¼confidence interval; F¼female; IC¼incomplete resection; M¼male; No.¼number; PF¼posterior fossa; Sc¼samples scored; ST¼supratentorial.
aThe median age at diagnosis of the primary tumours was 3.8 years (range, 8 months to 14.9 years). Significant P-values (o0.05) are given in bold.
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trates that there is a distinction between genetic events occurring
in children of different ages.
S100A4 and S100A6 are clearly differentially expressed in
paediatric ependymoma and can be used to distinguish clinically
and biologically relevant subgroups. Expanding our study to the
gene expression levels across six other brain tumour types showed
that for a number of S100 genes the expression levels were notably
elevated in a particular tumour type. For example, S100A16 is
elevated in grade I astrocytoma and S100A11 in glioblastoma. In
contrast, several S100 genes had similar expression levels across
multiple tumour types, including S100A14, S100A13 and S100A3.
Similar expression profiles were also seen across all tumour types
for S100A8 and S100A9 but this could be attributed to their
function in which they form a heterodimer complex (Vogl et al,
2006). These findings highlight the importance of further
investigation of specific members of the S100 family to understand
their function in ependymoma and other brain tumours.
CHI3L1, located on 1q32.1, was the most overexpressed gene in
the relapse pair with 1q gain and was also one of the most
upregulated genes in ependymoma when compared with ‘normal’
brain. Immunohistochemistry of CHI3L1 revealed a correlation
between the immunostaining and necrosis. Notably, the TMAs
were constructed by selecting three representative areas from each
tumour, in this process we tended to avoid areas of necrosis,
however, in five cases necrosis was present. In these five cases
staining showed that CHI3L1 was more highly expressed in the
cytoplasm of tumour cells adjacent to the necrotic regions (Figure
2I and J). CHI3L1 encodes for YKL-40, which is a secreted protein
that has been reported to be overexpressed in a number of
different cancers, including glioma, and has been proposed as a
new therapeutic target (Pelloski et al, 2005; Johansen et al, 2007).
The role of CHI3L1 in cancer is unknown, but it has been
suggested that it has a function in a number of pro-survival
processes (Johansen et al, 2007). In glioblastoma (GBM), where
necrosis is a characteristic, both CHI3L1 expression and necrosis
are associated with poor prognosis (Burger and Green, 1987; Raza
et al, 2002; Pelloski et al, 2005; Homma et al, 2006; Kleihues et al,
2007). In ependymoma, we did not find a correlation with
prognosis, thus, raising the possibility that CHI3L1 is a marker
of necrosis rather than of adverse biology per se. These obser-
vations in GBMs and our findings in ependymoma suggest a link
between CHI3L1 and necrosis in brain tumours. As the cores
represented on the TMA are selected to avoid regions of necrosis,
our findings maybe an under-representation and further investiga-
tion of CHI3L1 expression on whole tissue sections is necessary.
Previously we identified gain of 1q as one of the most common
gains in primary and recurrent ependymoma and demonstrated a
tendency that patients with gain of 1q have a poorer outcome
(Dyer et al, 2002). The aim of this study was to investigate 1q in
ependymoma to gain insight into the role of genes located in this
region. In this study, we have identified members of the S100
family located within the commonly gained amplicon 1q21.3 and
provide evidence of their differential expression in clinical
subgroups of paediatric ependymoma: S100A4 is associated with
patients of a very young age at diagnosis and S100A6 with
supratentorial tumour location. We also demonstrated a link
between CHI3L1 protein expression and necrosis. However, we are
yet to elucidate the underlying mechanism by which 1q gain
confers adverse biological behaviour in paediatric ependymoma.
We are now extending this study to a larger tumour cohort to
further unravel the underlying biology of 1q in this complex
tumour.
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